|
Volumn 6, Issue 1, 2013, Pages
|
CMR-verified interstitial myocardial fibrosis as a marker of subclinical cardiac involvement in LMNA mutation carriers
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALDOSTERONE[_DLNK ENDOGENOUS COMPOUND];
AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
CATECHOLAMINE;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
GADODIAMIDE;
GADOLINIUM;
LAMIN A;
UNCLASSIFIED DRUG;
ALDOSTERONE BLOOD LEVEL;
ATRIOVENTRICULAR BLOCK;
ATRIOVENTRICULAR CONDUCTION;
BLOOD SAMPLING;
CARDIOPULMONARY EXERCISE TEST;
CARDIOVASCULAR MAGNETIC RESONANCE;
CATECHOLAMINE BLOOD LEVEL;
ELECTROCARDIOGRAPHY MONITORING;
FIRST DEGREE ATRIOVENTRICULAR BLOCK;
GENE EXPRESSION;
GENE MUTATION;
GENOTYPE;
HEART LEFT VENTRICLE EJECTION FRACTION;
HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME;
HEART LEFT VENTRICLE FAILURE;
HEART MUSCLE FIBROSIS;
HEART VENTRICLE SIZE;
HEMATOCRIT;
HOLTER MONITORING;
HUMAN;
INCIDENCE;
LETTER;
PATIENT REFERRAL;
PLASMA RENIN ACTIVITY;
PRIORITY JOURNAL;
RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;
|
EID: 84893042853
PISSN: 1936878X
EISSN: 18767591
Source Type: Journal
DOI: 10.1016/j.jcmg.2012.06.013 Document Type: Letter |
Times cited : (43)
|
References (4)
|